HALO Award Disclosure
Appelhans Dannielle · SEC Form 4 · Filed Sep 2, 2026
Award
Calculated transaction value
$0
Appelhans Dannielle Director
HALO
Transaction date
Sep 1, 2026
Public filing date
Sep 2, 2026
Filing lag
Filed 1 day later
HALO daily price context
Close on/before transaction
$107.72
Sep 1, 2026
Close before public filing
$107.72
Sep 1, 2026
Return since public filing
-0.48%
Through Sep 11, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Derivative
- Security
- Option to Purchase Common Stock on Common Stock
- Quantity / price
- 1,778 shares @ $0
- SEC ownership
- Direct
- Transaction code
- A
- Form
- 4
- Filing identifier
- 0001159036-26-000117
Filing cohort
Transactions in this filing
Showing 2 of 2
Trades
2
Issuers
1
Estimated value
$0
Buys / sales
0 / 0
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Halozyme Therapeutics, Inc. HALO | Award | Sep 1, 2026 | $0 |
| Halozyme Therapeutics, Inc. HALO Current | Award | Sep 1, 2026 | $0 |